TEM: Tempus Labs Price-to-Revenue Coefficient

Brandmark of Tempus AI, Inc. (TEM)

The estimated P/S dynamics correlate with revenues from genomic analysis and data sales to pharma behemoths. The integration of AI into medicine for targeted therapy mitigates risks, while the aggressive hiring of data scientists via stock options strengthens the technical foundation. The current 8.90 figure represents the latest metric reading, reflecting market expectations regarding the capitalization and sales growth rates of Tempus AI, Inc (TEM).

TEM (Tempus AI) P/S Multiple history from 12/31/2024 to 11/13/2026

Analytical breakdowns for Tempus AI Inc (TEM)

- share price and consensus valuation forecast:
Fundamental company analysis:TEM (tempus.com)
Brand item of Tempus

For Tempus AI, Inc (TEM), with its scalable AI platform for precision medicine, the P/S multiple serves as a key indicator reflecting the market value of digital assets and data monetization potential. The price-to-sales ratio, illustrated by current P/S dynamics, allows for an assessment of the premium paid for future growth, where extreme values signal overheating and a downward trend indicates business undervaluation.

Competing companies

QGEN (qiagen.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple IONS (Ionis)|Price-to-Revenue Coefficient Repligen Corp (RGEN)|RNA - Price-to-Revenue Ratio|CRSP (CRISPR) - Market Cap to Revenue Ratio|WGS: P/S Multiple|Market Cap to Revenue ultragenyx.com|Market Cap to Revenue BEAM|SRPT (Sarepta Therapeutics) - Market Cap to Sales Volume|P/S Multiple TWST|TXG - Price to Sales|Price-to-Revenue Ratio Intellia Therapeutics NTLA|STOK - Market Cap to Revenue|BioLife Solutions - P/S Multiple|WVE (Wave Life Sciences Ltd) - Market Cap to Revenue Ratio|Maze Tx (MAZE) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio SION|PRME (Prime Medicine, Inc.) - P/S Multiple|P/S Multiple tayshagtx.com|Market Cap to Revenue QURE (uniQure)|Market Cap to Sales Volume MGTX|P/S Multiple RGNX (Regenxbio)|Solid Corp (SLDB) - Price to Sales|OCGN - Price-to-Revenue Ratio|pacb.com (PACB) - Market Cap to Revenue|Benitec Biopharma (BNTC) - Price-to-Revenue Ratio|Price-to-Sales Ratio DSGN (Design Therapeutics Inc)|Market Cap to Revenue RCKT|P/S Multiple 4D Molecular Corp|Price-to-Revenue Ratio Lexeo Therapeutics (LXEO)|Price-to-Revenue Coefficient korrobio.com|Editas Medicine - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio SLN|ProQR Therapeutics NV - P/S Multiple|CDXS - P/S Multiple|SGMO: P/S Multiple|NAUT - Price-to-Revenue Coefficient|Market Cap to Revenue MGX|DTIL: Market Capitalization-to-Revenue Ratio|P/S Multiple GBIO|Price-to-Revenue Coefficient Boundless Bio Inc|Price-to-Revenue Ratio Exicure XCUR|IMNN: Market Cap to Revenue Ratio|RXi Pharmaceuticals - P/S Multiple|Mustang Bio, Inc. (MBIO) - Market Cap to Revenue|RNAZ (transcodetherapeutics.com) - Market Cap to Revenue|BNGO: Market Cap to Sales Volume|APDN (Applied DNA Sciences) - P/S Multiple|Price to Sales bluebirdbio.com BLUE|Price-to-Revenue Ratio ImmunoPrecise Antibodies (IPA)|Market Cap to Revenue Omega Therapeutics Inc OMGA|P/S Multiple OMIC (Singular Genomics Systems Inc)|RGLS: Market Cap to Revenue Ratio|SYRS - Price-to-Revenue Ratio|TBIO (telesisbio.com) - Market Cap to Revenue Ratio|TCON: P/S Multiple|Unity Biotechnology Inc. (UBX) - P/S Multiple